An omics-based machine learning approach to predict diabetes progression: a RHAPSODY study.

Détails

Ressource 1Télécharger: 38374450_BIB_14192B042DAE.pdf (1208.26 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_14192B042DAE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
An omics-based machine learning approach to predict diabetes progression: a RHAPSODY study.
Périodique
Diabetologia
Auteur⸱e⸱s
Slieker R.C., Münch M., Donnelly L.A., Bouland G.A., Dragan I., Kuznetsov D., Elders PJM, Rutter G.A., Ibberson M., Pearson E.R., 't Hart L.M., van de Wiel M.A., Beulens JWJ
ISSN
1432-0428 (Electronic)
ISSN-L
0012-186X
Statut éditorial
Publié
Date de publication
05/2024
Peer-reviewed
Oui
Volume
67
Numéro
5
Pages
885-894
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
People with type 2 diabetes are heterogeneous in their disease trajectory, with some progressing more quickly to insulin initiation than others. Although classical biomarkers such as age, HbA <sub>1c</sub> and diabetes duration are associated with glycaemic progression, it is unclear how well such variables predict insulin initiation or requirement and whether newly identified markers have added predictive value.
In two prospective cohort studies as part of IMI-RHAPSODY, we investigated whether clinical variables and three types of molecular markers (metabolites, lipids, proteins) can predict time to insulin requirement using different machine learning approaches (lasso, ridge, GRridge, random forest). Clinical variables included age, sex, HbA <sub>1c</sub> , HDL-cholesterol and C-peptide. Models were run with unpenalised clinical variables (i.e. always included in the model without weights) or penalised clinical variables, or without clinical variables. Model development was performed in one cohort and the model was applied in a second cohort. Model performance was evaluated using Harrel's C statistic.
Of the 585 individuals from the Hoorn Diabetes Care System (DCS) cohort, 69 required insulin during follow-up (1.0-11.4 years); of the 571 individuals in the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) cohort, 175 required insulin during follow-up (0.3-11.8 years). Overall, the clinical variables and proteins were selected in the different models most often, followed by the metabolites. The most frequently selected clinical variables were HbA <sub>1c</sub> (18 of the 36 models, 50%), age (15 models, 41.2%) and C-peptide (15 models, 41.2%). Base models (age, sex, BMI, HbA <sub>1c</sub> ) including only clinical variables performed moderately in both the DCS discovery cohort (C statistic 0.71 [95% CI 0.64, 0.79]) and the GoDARTS replication cohort (C 0.71 [95% CI 0.69, 0.75]). A more extensive model including HDL-cholesterol and C-peptide performed better in both cohorts (DCS, C 0.74 [95% CI 0.67, 0.81]; GoDARTS, C 0.73 [95% CI 0.69, 0.77]). Two proteins, lactadherin and proto-oncogene tyrosine-protein kinase receptor, were most consistently selected and slightly improved model performance.
Using machine learning approaches, we show that insulin requirement risk can be modestly well predicted by predominantly clinical variables. Inclusion of molecular markers improves the prognostic performance beyond that of clinical variables by up to 5%. Such prognostic models could be useful for identifying people with diabetes at high risk of progressing quickly to treatment intensification.
Summary statistics of lipidomic, proteomic and metabolomic data are available from a Shiny dashboard at https://rhapdata-app.vital-it.ch .
Mots-clé
Humans, Diabetes Mellitus, Type 2/metabolism, Prospective Studies, C-Peptide, Proteomics, Insulin/therapeutic use, Biomarkers, Machine Learning, Cholesterol, Machine learning, Prediction model, Progression, Type 2 diabetes
Pubmed
Web of science
Open Access
Oui
Création de la notice
26/02/2024 9:22
Dernière modification de la notice
09/08/2024 14:56
Données d'usage